Risultati per: Livelli molto elevati di Colesterolo HDL-C associati al rischio di demenza

Circulation, Volume 150, Issue Suppl_1, Page A4142200-A4142200, November 12, 2024. Introduction:Apolipoprotein B (ApoB) is a better marker of residual risk for cardiovascular disease in patients treated with lipid-lowering therapy (LLT) than low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). However, it is unclear if treating to an apoB target is more cost-effective than treating to an LDL-C or non-HDL-C target.Methods:We used the CVD Policy Model, a validated computer simulation model, to estimate the clinical and economic outcomes associated with atherogenic lipid targets for LLT in a cohort of statin-eligible and ASCVD-free U.S. adults. We considered non-HDL-C, and apoB targets for intensification of LLT. Treatments considered were intermediate-intensity statin therapy, high-intensity statin therapy, and ezetimibe, intensified in that order. Upon entering the model, all individuals commenced statin therapy. Under ‘usual care,’ patients with LDL-C ≥100 mg/dL after three months of treatment were escalated to higher-intensity treatment. Under non-HDL-C and apoB testing strategies, LLT was escalated if patients had non-HDL-C ≥119 mg/dL and apoB ≥78.7 mg/dL, respectively, based on percentile equivalence to the LDL-C target. The primary outcomes for our study were healthcare costs (2023 U.S. dollars) and quality-adjusted life years (QALYs). Secondary outcomes were CVD events prevented and life years gained. A lifetime horizon was adopted with a health sector perspective. Future costs and QALYs were discounted at 3% annually.Results:In a sex-balanced simulated cohort of 500,000 individuals, both non-HDL-C and apoB testing produced more QALYs and fewer costs than usual care (LDL-C target). Intensification based on apoB, produced 1,416 more QALYs than non-HDL-C-guided intensification, saving around $29,300,000 over the lifecourse of the simulated cohort. Compared to non-HDL-C testing, apoB testing would lead to 1,233 fewer CVD events and 3,800 more life years. Health gains were greater for men, though apoB screening was cost-saving (i.e., higher QALYs, lower cost) when compared to LDL-C and non-HDL-C testing for men and women.Conclusion:Making LLT intensification decisions based on apoB instead of LDL-C or non-HDL-C would save costs while improving population health.

Circulation, Volume 150, Issue Suppl_1, Page A4141018-A4141018, November 12, 2024. Background:It is unclear if the novel, functionally unidentified HDL cholesterol subtypes HDL-2b and HDL-3 can be used to predict acute myocardial infarction (AMI).Methods:This cross-sectional study comprised 1,200 hospitalized patients with AMI identified using ICD-9 coding. The Gensini score was used to assess stenosis severity, defining patients as severe (score ≥50) or mild to moderate (score

In nove anni utenti raddoppiati, in lieve calo i suicidi

‘Persistente infezione nei corridoi migratori’

Disturbo da lentezza motoria e deficit di memoria

Fino al 30% è interessato da qualche forma di malnutrizione

Con tipo 2 raddoppia rischio Alzheimer e demenza vascolare

Andrologi, attenzione a carne rossa e pasti fuori orario

Andrologi, attenzione a carne rossa e pasti fuori orario

Congresso allergologi, ‘accesso equo a cure su tutto territorio’

Mangiacavalli: ‘Serve un Commissario Straordinario?’

Logopedisti: “Impatto sulla scuola e sul futuro lavorativo dei bambini”

In fondazione Prada la seconda giornata di incontri

Osservatorio Nomisma, per 8 medicinali su 10 esiste l’equivalente

Unicef, mancano alimenti terapeutici; servono 165 milioni